Fig 2: ROC curves of clinical model and corresponding urinary biomarkers model on day 0 for predicting renal non-recovery. Day 0 means the day of AKI diagnosis. aCompared with clinical model. Clinical model included non-renal SOFA score and AKI stage. AUC area under the receiver operating characteristics curve, CCL14 C–C motif chemokine ligand 14, TIMP-2 tissue inhibitor of metalloproteinases-2, IGFBP-7 insulin-like growth factor-binding protein 7

Fig 3: Urinary [TIMP-2]•[IGFBP7] and CCL14 levels at AKI diagnosis in renal recovery and renal non-recovery group. a: The comparison of urinary [TIMP-2]•[IGFBP7] levels of renal recovery and non-recovery. b: The comparison of urinary CCL14 levels of renal recovery and non-recovery. Abbreviations: SA-AKI, sepsis-associated acute kidney injury; TIMP-2, Tissue inhibitor of metalloproteinase-2; IGFBP7, Insulin-like growth factor-binding protein 7; CCL14, C-C motif chemokine ligand 14

Fig 4: The predictive value of biomarkers for 30-day mortality after AKI. The ROC curves of urinary [TIMP-2]•[IGFBP7] and CCL14 for predicting 30-day mortality after AKI. Abbreviations: ROC, receiver operating characteristic; AUC, area under the ROC. TIMP-2, Tissue inhibitor of metalloproteinase-2; IGFBP7, Insulin-like growth factor-binding protein 7; CCL14, C-C motif chemokine ligand 14

Fig 5: The predictive value of [TIMP-2]•[IGFBP7], CCL14 at AKI diagnosis and combined model for renal non-recovery. AUCs of [TIMP-2]•[IGFBP7], CCL14, and combined model( [TIMP-2]•[IGFBP7] - CCL14) for renal non-recovery. Abbreviations: ROC, receiver operating characteristic; AUC, the area under the curve; AKI, acute kidney injury; SA-AKI, sepsis-associated acute kidney injury; TIMP-2, Tissue inhibitor of metalloproteinase-2; IGFBP7, Insulin-like growth factor-binding protein 7; CCL14, C-C motif chemokine ligand 14